FY2024 EPS Estimates for OptiNose Raised by HC Wainwright

OptiNose, Inc. (NASDAQ:OPTN) – Investment analysts at HC Wainwright raised their FY2024 EPS estimates for shares of OptiNose in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($0.18) per share for the year, up from their prior forecast of ($0.22). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for OptiNose’s current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for OptiNose’s FY2025 earnings at ($0.03) EPS, FY2026 earnings at $0.08 EPS, FY2027 earnings at $0.23 EPS and FY2028 earnings at $0.35 EPS.

Separately, Piper Sandler reduced their price target on shares of OptiNose from $3.00 to $1.00 and set an “overweight” rating for the company in a research report on Wednesday.

OptiNose Price Performance

OPTN stock opened at $0.46 on Friday. The company’s 50-day moving average price is $0.76 and its 200 day moving average price is $0.96. OptiNose has a 52 week low of $0.44 and a 52 week high of $2.10.

Hedge Funds Weigh In On OptiNose

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in shares of OptiNose by 1.5% in the first quarter. Vanguard Group Inc. now owns 4,242,610 shares of the company’s stock valued at $6,194,000 after purchasing an additional 62,906 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in OptiNose by 2.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,920,309 shares of the company’s stock valued at $3,037,000 after buying an additional 81,233 shares in the last quarter. XTX Topco Ltd acquired a new stake in OptiNose during the 2nd quarter valued at $88,000. GSA Capital Partners LLP purchased a new position in OptiNose during the third quarter worth $61,000. Finally, Squarepoint Ops LLC raised its holdings in shares of OptiNose by 173.7% in the second quarter. Squarepoint Ops LLC now owns 171,610 shares of the company’s stock worth $178,000 after acquiring an additional 108,903 shares during the last quarter. 85.60% of the stock is currently owned by hedge funds and other institutional investors.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.